Telomir Pharmaceuticals, Inc. (TELO): Nasdaq/NYSE listing notice — Telomir receives Nasdaq non-compliance notice for missing annual meeting; has until Feb 23 to submit plan

Telomir Pharmaceuticals, Inc.

Received Nasdaq notice on Jan 8, 2026 for failure to hold annual meeting within 12 months of fiscal year end (Rule 5620(a)).
No immediate delisting; trading continues. Must submit compliance plan by Feb 23, 2026.
Preliminary proxy filed Nov 20, 2025 still under SEC review; expects to hold meeting promptly after clearance.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Telomir Pharmaceuticals, Inc. received a nasdaq deficiency notice notice regarding other (rules 5620(a)).

Exchange: nasdaq
Notice: deficiency notice
Rules: 5620(a)

Exact text from the filing

January 8, 2026, the Company received a written notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company is not in compliance with Nasdaq Listing Rule 5620(a), which requires listed companies to hold an annual meeting of shareholders within twelve months of the end of their fiscal year. The Notice does not result in the immediate delisting of the Company’s securities and has no current effect on the listing or trading of the Company’s common stock on the Nasdaq Capital Market. Pursuant to the Notice, the Company has

View on SEC.gov

20 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Telomir Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-26-001170

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.